HR Execs on the Move

Zavante Therapeutics

www.zavante.com

 
Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.zavante.com
  • 12670 High Bluff Dr
    San Diego, CA USA 92130
  • Phone: 858.705.2365

Executives

Name Title Contact Details

Similar Companies

Nanogenix

Nanogenix Inc. is a biotechnology company that focuses on developing and commercializing novel cancer therapies for patients in high unmet need disease categories.

Advarra

Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster.

Integrated Nano-Technologies

Integrated Nano-Technologies is a Henrietta, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.

Unique Pharmaceuticals

Unique Pharmaceuticals is a Temple, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.